bioAffinity Technologies, Inc. announced on April 17, 2025, the implementation of key efficiency measures for its flagship product, CyPath® Lung. These improvements are projected to decrease the time required to acquire sample data for analysis by nearly 50% and reduce the cost of sample processing by approximately 60%.
The enhancements streamline lab processing and data acquisition workflows, reduce reagent usage, and cut laboratory supply costs. These changes were made without altering the test itself, patient sample collection, or the method of data acquisition and analysis, thus maintaining clinical performance.
The company expects these improvements to result in a greater than 10% increase in overall throughput and a greater than 25% decrease in unit cost. This operational optimization enhances the scalability and potential profitability of CyPath® Lung, making it a more cost-effective and accessible diagnostic tool for early lung cancer detection.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.